292 related articles for article (PubMed ID: 26556769)
1. Ten-year survival after epithelial ovarian cancer is not associated with BRCA mutation status.
Kotsopoulos J; Rosen B; Fan I; Moody J; McLaughlin JR; Risch H; May T; Sun P; Narod SA
Gynecol Oncol; 2016 Jan; 140(1):42-7. PubMed ID: 26556769
[TBL] [Abstract][Full Text] [Related]
2. Young Israeli women with epithelial ovarian cancer: prevalence of BRCA mutations and clinical correlates.
Helpman L; Zidan O; Friedman E; Kalfon S; Perri T; Ben-Baruch G; Korach J
J Gynecol Oncol; 2017 Sep; 28(5):e61. PubMed ID: 28657222
[TBL] [Abstract][Full Text] [Related]
3. Risk of breast cancer after a diagnosis of ovarian cancer in BRCA mutation carriers: Is preventive mastectomy warranted?
McGee J; Giannakeas V; Karlan B; Lubinski J; Gronwald J; Rosen B; McLaughlin J; Risch H; Sun P; Foulkes WD; Neuhausen SL; Kotsopoulos J; Narod SA;
Gynecol Oncol; 2017 May; 145(2):346-351. PubMed ID: 28314588
[TBL] [Abstract][Full Text] [Related]
4. Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer.
Candido-dos-Reis FJ; Song H; Goode EL; Cunningham JM; Fridley BL; Larson MC; Alsop K; Dicks E; Harrington P; Ramus SJ; de Fazio A; Mitchell G; Fereday S; Bolton KL; Gourley C; Michie C; Karlan B; Lester J; Walsh C; Cass I; Olsson H; Gore M; Benitez JJ; Garcia MJ; Andrulis I; Mulligan AM; Glendon G; Blanco I; Lazaro C; Whittemore AS; McGuire V; Sieh W; Montagna M; Alducci E; Sadetzki S; Chetrit A; Kwong A; Kjaer SK; Jensen A; Høgdall E; Neuhausen S; Nussbaum R; Daly M; Greene MH; Mai PL; Loud JT; Moysich K; Toland AE; Lambrechts D; Ellis S; Frost D; Brenton JD; Tischkowitz M; Easton DF; Antoniou A; Chenevix-Trench G; Gayther SA; Bowtell D; Pharoah PD; ; ;
Clin Cancer Res; 2015 Feb; 21(3):652-7. PubMed ID: 25398451
[TBL] [Abstract][Full Text] [Related]
5. BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer.
Dann RB; DeLoia JA; Timms KM; Zorn KK; Potter J; Flake DD; Lanchbury JS; Krivak TC
Gynecol Oncol; 2012 Jun; 125(3):677-82. PubMed ID: 22406760
[TBL] [Abstract][Full Text] [Related]
6. Impact of primary platinum-free interval and BRCA1/2 mutation status on treatment and survival in patients with recurrent ovarian cancer.
Bookman MA; Tyczynski JE; Espirito JL; Wilson TW; Fernandes AW
Gynecol Oncol; 2017 Jul; 146(1):58-63. PubMed ID: 28454659
[TBL] [Abstract][Full Text] [Related]
7. Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer.
Hyman DM; Zhou Q; Iasonos A; Grisham RN; Arnold AG; Phillips MF; Bhatia J; Levine DA; Aghajanian C; Offit K; Barakat RR; Spriggs DR; Kauff ND
Cancer; 2012 Aug; 118(15):3703-9. PubMed ID: 22139894
[TBL] [Abstract][Full Text] [Related]
8. Long-term ovarian cancer survival associated with mutation in BRCA1 or BRCA2.
McLaughlin JR; Rosen B; Moody J; Pal T; Fan I; Shaw PA; Risch HA; Sellers TA; Sun P; Narod SA
J Natl Cancer Inst; 2013 Jan; 105(2):141-8. PubMed ID: 23257159
[TBL] [Abstract][Full Text] [Related]
9. Impact of germline mutations in cancer-predisposing genes on long-term survival in patients with epithelial ovarian cancer.
Kotsopoulos J; Zamani N; Rosen B; McLaughlin JR; Risch HA; Kim SJ; Sun P; Akbari MR; Narod SA
Br J Cancer; 2022 Sep; 127(5):879-885. PubMed ID: 35710751
[TBL] [Abstract][Full Text] [Related]
10. Fifteen-year survival of invasive epithelial ovarian cancer in women with BRCA1/2 mutations - the National Israeli Study of Ovarian Cancer.
Lavie O; Chetrit A; Novikov I; Sadetzki S;
Gynecol Oncol; 2019 May; 153(2):320-325. PubMed ID: 30872026
[TBL] [Abstract][Full Text] [Related]
11. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.
Pal T; Permuth-Wey J; Betts JA; Krischer JP; Fiorica J; Arango H; LaPolla J; Hoffman M; Martino MA; Wakeley K; Wilbanks G; Nicosia S; Cantor A; Sutphen R
Cancer; 2005 Dec; 104(12):2807-16. PubMed ID: 16284991
[TBL] [Abstract][Full Text] [Related]
12. Fertility treatments and invasive epithelial ovarian cancer risk in Jewish Israeli BRCA1 or BRCA2 mutation carriers.
Perri T; Lifshitz D; Sadetzki S; Oberman B; Meirow D; Ben-Baruch G; Friedman E; Korach J
Fertil Steril; 2015 May; 103(5):1305-12. PubMed ID: 25792249
[TBL] [Abstract][Full Text] [Related]
13. A targeted analysis identifies a high frequency of BRCA1 and BRCA2 mutation carriers in women with ovarian cancer from a founder population.
Belanger MH; Dolman L; Arcand SL; Shen Z; Chong G; Mes-Masson AM; Provencher D; Tonin PN
J Ovarian Res; 2015 Mar; 8():1. PubMed ID: 25884701
[TBL] [Abstract][Full Text] [Related]
14. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.
Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A
Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976
[TBL] [Abstract][Full Text] [Related]
15. Effect of BRCA mutational status on survival outcome in advanced-stage high-grade serous ovarian cancer.
Kim SI; Lee M; Kim HS; Chung HH; Kim JW; Park NH; Song YS
J Ovarian Res; 2019 May; 12(1):40. PubMed ID: 31064392
[TBL] [Abstract][Full Text] [Related]
16. Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer.
Chetrit A; Hirsh-Yechezkel G; Ben-David Y; Lubin F; Friedman E; Sadetzki S
J Clin Oncol; 2008 Jan; 26(1):20-5. PubMed ID: 18165636
[TBL] [Abstract][Full Text] [Related]
17. Histopathological characteristics of BRCA1- and BRCA2-associated intraperitoneal cancer: a clinic-based study.
Piek JM; Torrenga B; Hermsen B; Verheijen RH; Zweemer RP; Gille JJ; Kenemans P; van Diest PJ; Menko FH
Fam Cancer; 2003; 2(2):73-8. PubMed ID: 14574155
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer.
Boyd J; Sonoda Y; Federici MG; Bogomolniy F; Rhei E; Maresco DL; Saigo PE; Almadrones LA; Barakat RR; Brown CL; Chi DS; Curtin JP; Poynor EA; Hoskins WJ
JAMA; 2000 May; 283(17):2260-5. PubMed ID: 10807385
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Clinical Outcomes of
Eoh KJ; Park HS; Park JS; Lee ST; Han J; Lee JY; Kim SW; Kim S; Kim YT; Nam EJ
Cancer Res Treat; 2017 Apr; 49(2):408-415. PubMed ID: 27488874
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological features of women with epithelial ovarian cancer and double heterozygosity for BRCA1 and BRCA2: A systematic review and case report analysis.
Le Page C; Rahimi K; Rodrigues M; Heinzelmann-Schwarz V; Recio N; Tommasi S; Bataillon G; Portelance L; Golmard L; Meunier L; Tonin PN; Gotlieb W; Yasmeen A; Ray-Coquard I; Labidi-Galy SI; Provencher D; Mes-Masson AM
Gynecol Oncol; 2020 Feb; 156(2):377-386. PubMed ID: 31753525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]